Latest & greatest articles for hepatitis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hepatitis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on hepatitis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for hepatitis

181. Animal models for the study of hepatitis B virus infection Full Text available with Trip Pro

Animal models for the study of hepatitis B virus infection Even with an effective vaccine, an estimated 240 million people are chronically infected with hepatitis B virus (HBV) worldwide. Current antiviral therapies, including interferon and nucleot(s)ide analogues, rarely cure chronic hepatitis B. Animal models are very crucial for understanding the pathogenesis of chronic hepatitis B and developing new therapeutic drugs or strategies. HBV can only infect humans and chimpanzees, with the use

2018 Zoological research

182. Elucidating the differences in pathogenicity between hepatitis E virus genotypes: The quest continues Full Text available with Trip Pro

Elucidating the differences in pathogenicity between hepatitis E virus genotypes: The quest continues 29404519 2018 11 13 2471-254X 2 2 2018 02 Hepatology communications Hepatol Commun Elucidating the differences in pathogenicity between hepatitis E virus genotypes: The quest continues. 128-130 10.1002/hep4.1152 Vercouter Ann-Sofie AS Laboratory of Liver Infectious Diseases Ghent University Ghent Belgium. Meuleman Philip P Laboratory of Liver Infectious Diseases Ghent University Ghent Belgium

2018 Hepatology communications

183. Glecaprevir?pibrentasvir for treating chronic hepatitis C

Glecaprevir?pibrentasvir for treating chronic hepatitis C Glecapre Glecaprevir–pibrentasvir for treating vir–pibrentasvir for treating chronic hepatitis C chronic hepatitis C T echnology appraisal guidance Published: 24 January 2018 nice.org.uk/guidance/ta499 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance represent the view of NICE (...) . Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Glecaprevir–pibrentasvir for treating chronic hepatitis C (TA499) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 14Contents Contents 1 Recommendations 4 2 Information about glecaprevir

2018 National Institute for Health and Clinical Excellence - Technology Appraisals

184. Core IM: 5 Pearls on Chronic Hepatitis B Part 2: Management

Core IM: 5 Pearls on Chronic Hepatitis B Part 2: Management Core IM: 5 Pearls on Chronic Hepatitis B Part 2: Management – Clinical Correlations Search Core IM: 5 Pearls on Chronic Hepatitis B Part 2: Management January 31, 2018 3 min read Podcast: | Subscribe: | By Amy Shen Tang MD, Marty Fried MD and Shreya P. Trivedi MD; Illustration by Michelle Lo, MD & Amy Ou, MD. Quiz yourself on the following 5 Pearls on Chronic Hepatitis B (HBV) Management Time Stamps What is the focused history (...) 5: HCC screening is based on risk factors such as family history of HCC, personal history of cirrhosis, ethnicity and sex of the patient with chronic hepatitis B. It starts at the time of diagnosis for African patients, age 40 for Asian men, age 50 for Asian women. Also, all patients w/ cirrhosis or a family hx of liver cancer should get routine screening. The AASLD recommends HCC screening with liver US every 6 months with or without serum alpha fetoprotein (AFP). References Terrault, N

2018 Clinical Correlations

185. [Sofosbuvir (hepatitis C in adolescents) - benefit assessment according to õ35a Social Code Book V]

[Sofosbuvir (hepatitis C in adolescents) - benefit assessment according to õ35a Social Code Book V] Sofosbuvir (chronische hepatitis C bei Jugendlichen): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-55 [Sofosbuvir (hepatitis C in adolescents) - benefit assessment according to §35a Social Code Book V] Sofosbuvir (chronische hepatitis C bei Jugendlichen): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-55 [Sofosbuvir (hepatitis C in adolescents) - benefit (...) assessment according to §35a Social Code Book V] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Sofosbuvir (chronische hepatitis C bei Jugendlichen): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-55

2018 Health Technology Assessment (HTA) Database.

186. HLA genotype does not appear to influence long-term antibody response to hepatitis B vaccine

HLA genotype does not appear to influence long-term antibody response to hepatitis B vaccine HLA genotype does not appear to influence long-term antibody response to hepatitis B vaccine - Evidencias en pediatría Searching, please wait Show menu Library Management You did not add any article to your library yet. | Search Evidence-Based decision making Evidence-Based decision making Show menu Library Management You did not add any article to your library yet. × User Password Log in × Reset (...) password If you need to reset your password please enter your email and click the Send button. You will receive an email to complete the process. Email Send × Library Management × December 2017. Volume 13. Number 4 HLA genotype does not appear to influence long-term antibody response to hepatitis B vaccine Rating: 0 (0 Votes) Reviewers: , . | Newsletter Free Subscription Regularly recieve most recent articles by e-mail Subscribe × Newsletter subscription: Email Confirm email I accept the journal’s

2018 Evidencias en Pediatría

187. Assessing the impact and cost-effectiveness of needle/syringe provision and opiate substitution therapy on hepatitis C transmission among people who inject drugs in the United Kingdom: analysis of pooled datasets and economic modelling

Assessing the impact and cost-effectiveness of needle/syringe provision and opiate substitution therapy on hepatitis C transmission among people who inject drugs in the United Kingdom: analysis of pooled datasets and economic modelling Assessing the impact and cost-effectiveness of needle/syringe provision and opiate substitution therapy on hepatitis C transmission among people who inject drugs in the United Kingdom: analysis of pooled datasets and economic modelling Assessing the impact (...) and cost-effectiveness of needle/syringe provision and opiate substitution therapy on hepatitis C transmission among people who inject drugs in the United Kingdom: analysis of pooled datasets and economic modelling Platt L, Sweeney S, Ward Z, Guinness L, Hickman M, Hope V, Hutchinson S, Maher L, Iversen J, Craine N, Taylor A, Munro A, Parry J, Smith J & Vickerman P Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation

2018 Health Technology Assessment (HTA) Database.

188. [Sofosbuvir/velpatasvir/voxilaprevir (chronic hepatitis C) - benefit assessment according to õ35a Social Code Book V]

[Sofosbuvir/velpatasvir/voxilaprevir (chronic hepatitis C) - benefit assessment according to õ35a Social Code Book V] Sofosbuvir/velpatasvir/ voxilaprevir (chronische hepatitis C): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-35 [Sofosbuvir/velpatasvir/voxilaprevir (chronic hepatitis C) – benefit assessment according to §35a Social Code Book V] Sofosbuvir/velpatasvir/ voxilaprevir (chronische hepatitis C): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-35 (...) [Sofosbuvir/velpatasvir/voxilaprevir (chronic hepatitis C) – benefit assessment according to §35a Social Code Book V] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Sofosbuvir/velpatasvir/ voxilaprevir (chronische

2018 Health Technology Assessment (HTA) Database.

189. [Ledipasvir/sofosbuvir (hepatitis C) - benefit assessment according to õ35a Social Code Book V]

[Ledipasvir/sofosbuvir (hepatitis C) - benefit assessment according to õ35a Social Code Book V] Ledipasvir/Sofosbuvir (chronische Hepatitis C bei Jugendlichen): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-41 [Ledipasvir/sofosbuvir (hepatitis C) – benefit assessment according to §35a Social Code Book V] Ledipasvir/Sofosbuvir (chronische Hepatitis C bei Jugendlichen): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-41 [Ledipasvir/sofosbuvir (hepatitis C (...) ) – benefit assessment according to §35a Social Code Book V] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Ledipasvir/Sofosbuvir (chronische Hepatitis C bei Jugendlichen): nutzenbewertung gemäß § 35a SGB V

2018 Health Technology Assessment (HTA) Database.

190. [Glecaprevir/pibrentasvir (chronic hepatitis C) - benefit assessment according to õ 35a Social Code Book V]

[Glecaprevir/pibrentasvir (chronic hepatitis C) - benefit assessment according to õ 35a Social Code Book V] Glecaprevir/Pibrentasvir (chronische hepatitis C): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-34 [Glecaprevir/pibrentasvir (chronic hepatitis C) – benefit assessment according to § 35a Social Code Book V] Glecaprevir/Pibrentasvir (chronische hepatitis C): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-34 [Glecaprevir/pibrentasvir (chronic hepatitis (...) C) – benefit assessment according to § 35a Social Code Book V] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Glecaprevir/Pibrentasvir (chronische hepatitis C): nutzenbewertung gemäß § 35a SGB V

2018 Health Technology Assessment (HTA) Database.

191. Cardiovascular Involvement in Chronic Hepatitis C Virus Infections – Insight from Novel Antiviral Therapies Full Text available with Trip Pro

Cardiovascular Involvement in Chronic Hepatitis C Virus Infections – Insight from Novel Antiviral Therapies Whereas statistical association of hepatitis C virus (HCV) infection with cardiomyopathy is long known, establishment of a causal relationship has not been achieved so far. Patients with advanced heart failure (HF) are mostly unable to tolerate interferon (IFN)-based treatment, resulting in limited experience regarding the possible pathogenic role of HCV in this patient group. HCV

2018 Journal of clinical and translational hepatology

192. Host-Virus Protein Interaction Network Reveals the Involvement of Multiple Host Processes in the Life Cycle of Hepatitis E Virus Full Text available with Trip Pro

Host-Virus Protein Interaction Network Reveals the Involvement of Multiple Host Processes in the Life Cycle of Hepatitis E Virus Comprehensive knowledge of host-pathogen interactions is central to understand the life cycle of a pathogen and devise specific therapeutic strategies. Protein-protein interactions (PPIs) are key mediators of host-pathogen interactions. Hepatitis E virus (HEV) is a major cause of viral hepatitis in humans. Recent reports also demonstrate its extrahepatic (...) antivirals against HEV. IMPORTANCE Hepatitis E virus (HEV) is a pathogen that is transmitted by the fecal-oral route. Owing to the lack of an efficient laboratory model, the life cycle of the virus is poorly understood. During the course of infection, interactions between the viral and host proteins play essential roles, a clear understanding of which is essential to decode the life cycle of the virus. In this study, we identified the direct host interaction partners of all HEV proteins and generated

2018 mSystems

193. Inflammatory myopathy and autoimmune hepatitis in a patient with a flare of systemic lupus erythematosus: An exceptional association Full Text available with Trip Pro

Inflammatory myopathy and autoimmune hepatitis in a patient with a flare of systemic lupus erythematosus: An exceptional association Systemic lupus erythematosus (SLE) is an autoimmune disease with a wide clinical expression, and musculoskeletal manifestations are the most frequent manifestations of the disease. Digestive manifestations, however, are less prevalent, appearing in only 2%-30% of the patients. Among these cases, the association of SLE with autoimmune hepatitis (AIH) is considered (...) to be rare, with only a few cases documented in the medical literature. We present the only reported case to date of a patient diagnosed with SLE suffering from a flare with a simultaneous hepatic and muscular inflammatory involvement, both evidenced by biopsy.

2018 European journal of rheumatology

194. Preserved in vitro immunoreactivity in children receiving long-term immunosuppressive therapy due to inflammatory bowel disease or autoimmune hepatitis Full Text available with Trip Pro

Preserved in vitro immunoreactivity in children receiving long-term immunosuppressive therapy due to inflammatory bowel disease or autoimmune hepatitis Children with inflammatory bowel disease (IBD) or autoimmune hepatitis (AIH) are at risk for severe infections. This is partially a result of their chronic disease condition but, moreover, a side effect of their immunosuppressive therapy. Currently, vaccinations with live vaccines are regarded as contraindicated under immunosuppressive therapy

2018 Molecular and cellular pediatrics

195. Ribavirin in Acute Hepatitis E Infection in Patients with Gynecological Cancer: A Case Series Full Text available with Trip Pro

Ribavirin in Acute Hepatitis E Infection in Patients with Gynecological Cancer: A Case Series Hepatitis E virus infection is usually a self-limited disease. However, during the last years there has been growing evidence for prolonged and chronic infection occurring in patients with immunosuppression. Also patients with malignant and rheumatic diseases have been identified to be at risk for chronic hepatitis E. However, their course and prognosis are not well characterized and there have been (...) no reports of hepatitis E virus infection in patients with gynecological cancer. Here, we report three Caucasian females with breast and ovarian cancers presenting with elevation of aminotransferase levels during anticancer treatment. Although only few or no clinical hints suggested hepatitis E virus infection, the diagnosis of hepatitis E virus infection was confirmed by seroconversion, which might occur with some delay, and/or by polymerase chain reaction. While two patients had a self-limited course

2018 Journal of clinical and translational hepatology

196. Acute decompensation boosts hepatic collagen type III deposition and deteriorates experimental and human cirrhosis Full Text available with Trip Pro

Acute decompensation boosts hepatic collagen type III deposition and deteriorates experimental and human cirrhosis Patients with end-stage liver disease develop acute decompensation (AD) episodes, which become more frequent and might develop into acute-on-chronic liver failure (ACLF). However, it remains unknown how AD induces acceleration of liver disease. We hypothesized that remodeling of collagen type III plays a role in the acceleration of liver cirrhosis after AD and analyzed its (...) analyzed 2, 3, 4, 5, and 6 weeks after bile duct ligation (n = 5 each group). In 110 patients with decompensated liver cirrhosis who underwent a transjugular intrahepatic portosystemic shunt procedure for AD, clinical and laboratory parameters as well as Pro-C3 and C3M were measured in blood samples from portal and hepatic veins and were collected just before the transjugular intrahepatic portosystemic shunt placement and 1-3 weeks later. Animal studies showed increased markers of collagen type III

2018 Hepatology communications

197. Reply to the Letter to the editor 'Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus Sorafenib for advanced hepatocellular carcinoma: randomized phase II trial' by Fornaro et al. Full Text available with Trip Pro

Reply to the Letter to the editor 'Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus Sorafenib for advanced hepatocellular carcinoma: randomized phase II trial' by Fornaro et al. 28137738 2018 01 18 2018 12 02 1569-8041 28 4 2017 04 01 Annals of oncology : official journal of the European Society for Medical Oncology Ann. Oncol. Reply to the Letter to the editor 'Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus Sorafenib for advanced

2018 Annals of oncology : official journal of the European Society for Medical Oncology Controlled trial quality: uncertain

198. A new mechanism of action of glucagon‐like peptide‐1 agonist in hepatic steatosis: Promotion of hepatic insulin clearance through induction of carcinoembryonic antigen‐related cell adhesion molecule 1 Full Text available with Trip Pro

A new mechanism of action of glucagon‐like peptide‐1 agonist in hepatic steatosis: Promotion of hepatic insulin clearance through induction of carcinoembryonic antigen‐related cell adhesion molecule 1 29404506 2019 01 18 2471-254X 2 1 2018 01 Hepatology communications Hepatol Commun A new mechanism of action of glucagon-like peptide-1 agonist in hepatic steatosis: Promotion of hepatic insulin clearance through induction of carcinoembryonic antigen-related cell adhesion molecule 1. 9-12

2018 Hepatology communications

199. Sustained Responses in Chronic Hepatitis B Patients with Nucleos(t)ide Analogue Drug-resistance after Peg-interferon Alfa-2a Add-on Treatment: A Long-term Cohort Study Full Text available with Trip Pro

Sustained Responses in Chronic Hepatitis B Patients with Nucleos(t)ide Analogue Drug-resistance after Peg-interferon Alfa-2a Add-on Treatment: A Long-term Cohort Study Background and Aims: The use of additional nucleos(t)ide analogues (NAs) without cross-resistance to previously used NAs as a rescue therapy is recommended by most international guidelines for chronic hepatitis B patients with NA-resistance. We aimed to investigate the efficacy and safety of combination therapy of peg-interferon (...) (PegIFN) alfa-2a and NA in these patients, comparing to those who switch to an alternative NA therapy without cross-resistance. Methods: In this prospective, comparative and cohort study, data were collected from the patients' hospital records. Eligible patients were those with hepatitis B e antigen (HBeAg) positivity and resistance to one or more NAs. All patients were treated with alternative NA alone or in combination with PegIFN alfa-2a for 52 weeks or 72 weeks, respectively. HBeAg seroconversion

2018 Journal of clinical and translational hepatology

200. Hepatitis E virus replication and interferon responses in human placental cells Full Text available with Trip Pro

Hepatitis E virus replication and interferon responses in human placental cells Hepatitis E virus (HEV) is a member of the genus Orthohepevirus in the family Hepeviridae and the causative agent of hepatitis E in humans. HEV is a major health problem in developing countries, causing mortality rates up to 25% in pregnant women. However, these cases are mainly reported for HEV genotype (gt)1, while gt3 infections are usually associated with subclinical courses of disease. The pathogenic mechanisms

2018 Hepatology communications